EUCTR2010-019017-25-DE进行中（未招募）不适用
Efficacy of medical treatment with SOM230 LAR in patients with primary inoperable thymoma and/or with local recurrent thymoma to reduce tumor size
Freistaat Bayern, represented by Universität Regensburg0 个研究点开始时间: 2010年11月8日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female patients aged =18 years
- •2.Diagnosis of thymoma as assessed by biopsy and/or szintigraphy
- •3.Inoperability of thymoma or loco-regional metastases. Inoperability is defined as at least adherence of the tumor to the neighbored organs, suspicious to infiltrate neighbored organs or local metastasis so that R0 resection can not be expected and /or local recurrence of thymic tumor
- •4.Tumor stage: Thymomas of all WHO based histological subtypes (WHO A, AB, B1, B2, B3) (Rosai, 1999; Travis 2004) at Masaoka stage II to IVa based on histological examination of resection specimens or core biopsies.
- •5.Patients with and without thymoma associated paraneoplastic syndrome.
- •6.Performance status 0,1, or 2 (ECOG)
- •7.Patients for whom written informed consent to participate in the study has been obtained
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 13
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 3
排除标准
- •Patients having received radiolabeled somatostatin analogue therapy within the 6 months or any cytotoxic chemotherapy or interferon therapy within the 2 months prior to recording baseline symptoms
- •Patients who have undergone major surgery/surgical therapy for any cause within 1 month or surgical therapy of loco-regional metastases within the last 3 months before recording baseline symptoms
- •Patients who have received radiotherapy for any reason within the last 4 weeks and must have recovered from any side effects of radiotherapy before recording baseline symptoms
- •Patients who are not biochemically euthyroid
- •Diabetic patients on antidiabetic medications whose fasting blood glucose is poorly controlled as indicated by HbA1C > 8%
- •Patients with symptomatic cholelithiasis
- •Patients who have congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, ventricular fibrillation, clinically significant bradycardia, advanced heart block or a history of acute myocardial infarction within the six months preceding enrollment
- •Patients with QT related risk factors:
- •-QTcF at screening > 450 msec
- •-History of syncope or family history of idiopathic sudden death
- •-Sudden or clinically significant cardiac arrhythmias
- •-Risk factors for Torsades de Pointes such as hypokalemia, hypomagnesemia, cardiac failure, clinically significant / symptomatic bradycardia, or high-grade AV block
- •-Concomitant disease(s) that could prolong QT such as autonomic neuropathy (caused by diabetes or Parkinson’s disease), HIV, cirrhosis, uncontrolled hypothyroidism or cardiac failure
- •-Concomitant medication(s) known to increase the QT interval
- •Patients with potassium <3.0 mmol/L at study entry, magnesium <0.4 mmol/L at study entry, calcium <1.75 mmol/L at study entry, family history of long QT syndrome, and concomitant medications known to prolong the QT interval. If the electrolyte abnormalities are corrected prior to study commencement, the patient may become eligible for the trial.
- •Patients with liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis with serum bilirubin > 1.5 X ULN, serum albumin < 0.67 X LLN, and/or ALT or AST more than 2 X ULN for patients without liver metastases or ALT or AST more than 5X ULN for patients with documented liver metastases
- •Patients with additional active malignant disease within the last five years (with the exception of basal cell carcinoma or carcinoma in situ of the cervix)
- •Patients with the presence of active or suspected acute or chronic uncontrolled infection or with a history of immunocompromise, including a positive HIV test result (ELISA and Western blot). A HIV test will not be required; however, previous medical history will be reviewed
- •Patients with abnormal coagulation (PT or APTT elevated by 30% above normal limits)
- •Patients with WBC <2.5 X 109/L; Hgb <10 g/dL; PLT <100 X 109/L (patients with paraneoplastic pan-, leuco-, erythro- or thrombopenia can be included if this seems to be the only reason for pan-, leuco-, erythro- or thrombopenia)
- •Known hypersensitivity to somatostatin analogues or any component of the pasireotide or octreotide LAR or s.c. formulations
- •Patients who have any current or prior medical condition that may interfere with the conduct of the study or the evaluation of its results in the opinion of the investigator
- •Female patients who are pregnant or lactating, or are of childbe
研究者
相似试验
已完成
2 期
Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor SizePrimary Inoperable ThymomaLocal Recurrent ThymomaNCT02021942Prof. Dr. Berthold Schalke16
进行中（未招募）
不适用
Effectiveness of SOM230 In Treating Non-Functioning Pituitary Adenomasnon-functioning pitiutary adenomesMedDRA version: 9.1Level: LLTClassification code 10035079Term: Pituitary adenomaEUCTR2005-004413-15-DECedars Sinai Medical Center
招募中
不适用
Pilot study of SOM230 for Treatment of Graves’ OphthalmopathyDiseases of the eye and adnexaKCT0001645Yonsei University Health System, Severance Hospital20
已完成
2 期
Monthly SOM230C for Recurrent or Progressive MeningiomaMeningiomaNCT00859040Patrick Y. Wen, MD34
终止
2 期
Safety and Efficacy Study of SOM230 s.c. in Cluster HeadacheCluster Headache - Episodic and ChronicNCT02619617Novartis Pharmaceuticals28